Aarti Bashyal

Dr. Aarti Bashyal

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in Analytical Chemistry
Verified
Journal Article
Closed access
ABAarti Bashyal
Aarti Bashyal
JHJohn O. Hui
John O. Hui
TFTawnya Flick
Tawnya Flick
ADAndrew B. Dykstra
Andrew B. Dykstra
QZQingchun Zhang
Qingchun Zhang
JBJennifer S. Brodbelt
Jennifer S. Brodbelt

17 April 2024 in Antibodies
Verified
Journal Article
Open access
PDF file
EWEleanor Watts
Eleanor Watts
ABAarti Bashyal
Aarti Bashyal
SDSean Dunham
Sean Dunham
CCChristopher M. Crittenden
Christopher M. Crittenden
JBJennifer S. Brodbelt
Jennifer S. Brodbelt
As the development of new biotherapeutics advances, increasingly sophisticated tandem mass spectrometry methods are needed to characterize the most complex molecules, including antibody drug conjugates (ADCs). Lysine-linked ADCs, such as trastuzumab-emtansine (T-DM1), are among the most heterogeneous biotherapeutics. Here, we implement a workflow that combines limited proteolysis with HCD-triggered EThcD and UVPD mass spectrometry for the characterization of the resulting middle-down large-sized peptides of T-DM1. Fifty-three payload-containing peptides were identified, ranging in mass from 1.8 to 16.9 kDa, and leading to the unambiguous identification of 46 out of 92 possible conjugation sites. In addition, seven peptides were identified containing multiple payloads. The characterization of these types of heterogeneous peptides represents an important step in unraveling the combinatorial nature of lysine-conjugated ADCs.


28 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMary D. Cundiff
Mary D. Cundiff
CHChristina M. Hurley
Christina M. Hurley
JWJeremy D. Wong
Jeremy D. Wong
ABAarti Bashyal
Aarti Bashyal
JRJake Rosenberg
Jake Rosenberg
DKDaniel Adam Kraut
Daniel Adam Kraut
The ubiquitin-proteasome system (UPS) is responsible for the bulk of protein degradation in eukaryotic cells, but the factors that cause different substrates to be unfolded and degraded to different extents are still poorly understood. We previously showed that polyubiquitinated substrates were degraded with greater processivity (with a higher tendency to be unfolded and degraded than released) than ubiquitin-independent substrates. Thus, even though ubiquitin chains are removed before unfolding and degradation occur, they affect the unfolding of a protein domain. How do ubiquitin chains activate the proteasome’s unfolding ability? We investigated the roles of the three intrinsic proteasomal ubiquitin receptors - Rpn1, Rpn10 and Rpn13 - in this activation. We find that these receptors are required for substrate-mediated activation of the proteasome’s unfolding ability. Rpn13 plays the largest role, but there is also partial redundancy between receptors. The architecture of substrate ubiquitination determines which receptors are needed for maximal unfolding ability, and, in some cases, simultaneous engagement of ubiquitin by multiple receptors may be required. Our results suggest physical models for how ubiquitin receptors communicate with the proteasomal motor proteins.